Literature DB >> 3782409

High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma and urine.

C J Richardson, S G Ross, K L Blocka, R K Verbeeck.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782409     DOI: 10.1016/s0378-4347(00)83548-3

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  7 in total

1.  A lack of pharmacokinetic interaction between ranitidine and piroxicam.

Authors:  J S Dixon; L F Lacey; M E Pickup; S J Langley; M C Page
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta-cyclodextrin, in healthy subjects under single dose and steady-state conditions.

Authors:  X Deroubaix; A Stockis; A M Allemon; E Lebacq; D Acerbi; P Ventura
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Steady state pharmacokinetics of piroxicam in children with rheumatic diseases.

Authors:  A L Mäkelä; K T Olkkola; M J Mattila
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

5.  Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam.

Authors:  C J Richardson; K L Blocka; S G Ross; R K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Piroxicam-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states.

Authors:  C R Lee; J A Balfour
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

7.  Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat.

Authors:  J I Troconiz; L G Lopez-Bustamante; D Fos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.